Drug Safety

, Volume 35, Issue 12, pp 1085–1089 | Cite as

Communicating the New Pharmacovigilance Landscape

  • I. Ralph Edwards

The title above reflects the title of the 12th ISoP Annual Meeting held in Cancun, Mexico, from 30 October–2 November, which was ‘New Landscapes in Pharmacovigilance’. The Programme of the meeting included many aspects of pharmacovigilance (PV), as well as major overarching issues that continue to affect the way we see our jobs in improving medication safety and benefit-risk balance. Examples were (broad) the nature of evidence, perceptions of causality, and prevention; and then (more detailed) adherence to risk management plans, patient reporting, education; and (very detailed) the challenge of PV during a pilgrimage to Makkah, a riboflavin pregnancy register, and benefit and risk preferences in drugs to treat type II diabetes and some case reports.

All of the above examples, and many more, typify our rapidly expanding discipline. Most of us think this is the way to go, but not all. It seems necessary that we should at all times communicate our visions and more practical objectives...



The author has no conflicts of interest that are directly relevant to the content of this editorial.


  1. 1.
    Uppsala Monitoring Centre. Effective communications in pharmacovigilance [online]. Available from URL: [Accessed 2012 Oct 24]
  2. 2.
    Uppsala Monitoring Centre. Dialogue in pharmacovigilance: more effective communication [online]. Available from URL: [Accessed 2012 Oct 24]
  3. 3.
    WHO, Office of the United Nations High Commissioner for Human Rights. The right to health. Fact sheet 31, page 7 [online]. Available from URL: [Accessed 2012 Oct 24]
  4. 4.
    Smith CM. Origin and uses of primum non nocere: above all, do no harm!. J Clin Pharmacol 2005; 45(4): 371–7PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Uppsala Monitoring CentreUppsalaSweden

Personalised recommendations